XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Commitments and Contingencies - HETLIOZ - Narrative (Details) - HETLIOZ® - USD ($)	1 Months Ended		3 Months Ended	11 Months Ended	12 Months Ended	242 Months Ended
	Dec. 31, 2022	Jan. 31, 2014	Mar. 31, 2024	Nov. 30, 2022	Dec. 31, 2018	Mar. 31, 2024
Commitments and Contingencies [Line Items]
Acquisition of intangible assets		$ 8,000,000			$ 25,000,000	$ 37,500,000
Intangible assets capitalized						$ 33,000,000
Possible future milestone payment			$ 0
Royalty payment period			10 years
Percentage of future sublicense fees payable to third-party			mid-twenties
Non-US
Commitments and Contingencies [Line Items]
Royalty payable percentage on net sales			5.00%
U.S.
Commitments and Contingencies [Line Items]
Royalty payable percentage on net sales	5.00%			10.00%

X

- Definition

Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Commitments and contingencies.

+ References

No definition available.

+ Details

Name:	vnda_CommitmentsAndContingenciesLineItems
Namespace Prefix:	vnda_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones.

+ References

No definition available.

+ Details

Name:	vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
Namespace Prefix:	vnda_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Percentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property.

+ References

No definition available.

+ Details

Name:	vnda_PercentageOfFutureSublicenseFeesPayable
Namespace Prefix:	vnda_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty payable percentage under a contractual arrangement for use of technology or intellectual property.

+ References

No definition available.

+ Details

Name:	vnda_RoyaltyPayableOnNetSalesPercentage
Namespace Prefix:	vnda_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty Period

+ References

No definition available.

+ Details

Name:	vnda_RoyaltyPeriod
Namespace Prefix:	vnda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=vnda_HetliozMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: